Thus, our results showed that combined therapy with EPZ-5676 and rapamycin could reduce Celf2 KO + MA9 leukemia burden and prolong the survival time of Celf2 KO + MA9 AML mice by inhibiting both mTORC1 pathway and MLL-fusion target gene expression. This evidence concerns the gene CELF2 and leukemia.